개인구독
소속 기관이 없으신 경우, 개인 정기구독을 하시면 저렴하게
논문을 무제한 열람 이용할 수 있어요.
지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2021.9
- 수록면
- 596 - 604 (9page)
- DOI
- https://doi.org/10.5124/jkma.2021.64.9.596
이용수
초록· 키워드
오류제보하기
Background: Recently, the incidence and prevalence rates of inflammatory bowel disease (IBD) have increased worldwide, including in Korea. Although there has been considerable progress in the management of IBD following the discovery of biologic agents, 5-aminosalicylate (5-ASA) and immunomodulators are still considered cornerstones in the management of mild to moderate IBD.
Current Concepts: 5-ASA plays a key role in inducing remission in patients with mild to moderate ulcerative colitis. High doses of 5-ASA are more effective in inducing remission in patients with moderate ulcerative colitis, and combination therapy of oral 5-ASA and topical 5-ASA agents is recommended. Although the effect of 5-ASA in patients with Crohn disease is limited, high doses of 5-ASA can be effective for patients with mild disease, inflammatory behavior, and colonic involvement. Maintaining remission is essential for patients with IBD. Good doctor-patient relationships and encouraging drug adherence are recommended. Regarding drug adherence, a once-daily regimen is preferred for patients’ satisfaction. Thiopurines, the most important immunomodulators, show therapeutic benefits, such as steroid-sparing effects and remission maintenance in ulcerative colitis and Crohn disease after induction therapy.
However, several side effects, including severe leukopenia, can induce the discontinuation of thiopurines. Close monitoring and management decisions should be individualized according to the risk of relapse and adverse events.
Discussion and Conclusion: In conclusion, 5-ASA and immunomodulators are cornerstones in the management of IBD. As such, clinicians should have knowledge of these drugs and patients’ characteristics for proper prescription.
목차
등록된 정보가 없습니다.
참고문헌 (50)
참고문헌 신청
Molodecky NA / 2012 / Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review / Gastroenterology 142:46~54
Park SH / 2019 / A 30-year trend analysis in the epidemiology of inflammatory bowel disease in the Songpa-Kangdong District of Seoul, Korea in 1986-2015 / J Crohns Colitis 13:1410~1417
Hsu-Heng Yen / 2019 / Epidemiological trend in inflammatory bowel disease in Taiwan from 2001 to 2015: a nationwide population-based study / Intestinal research 17(1):54~62
Masoud M Malekzadeh / 2019 / Iranian Registry of Crohn’s and Colitis: study profile of first nation-wide inflammatory bowel disease registry in Middle East / Intestinal research 17(3):330~339
이광재 / 2015 / 염증성 장질환의 약물요법 / 대한의사협회지 58(1):57~63
Park SH / 2019 / A 30-year trend analysis in the epidemiology of inflammatory bowel disease in the Songpa-Kangdong District of Seoul, Korea in 1986-2015 / J Crohns Colitis 13:1410~1417
Hsu-Heng Yen / 2019 / Epidemiological trend in inflammatory bowel disease in Taiwan from 2001 to 2015: a nationwide population-based study / Intestinal research 17(1):54~62
Masoud M Malekzadeh / 2019 / Iranian Registry of Crohn’s and Colitis: study profile of first nation-wide inflammatory bowel disease registry in Middle East / Intestinal research 17(3):330~339
이광재 / 2015 / 염증성 장질환의 약물요법 / 대한의사협회지 58(1):57~63
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
염증성 장질환의 약물요법
대한의사협회지
2015 .01
-
우리나라 염증장질환의 현황
대한의사협회지
2021 .09
-
5-Aminosalicylic acid aggravates colitis mimicking exacerbation of ulcerative colitis
Intestinal research
2018 .01
-
Pathogenesis of Inflammatory Bowel Disease and Recent Advances in Biologic Therapies
Immune Network
2017 .02
-
염증장질환의 역학 및 진단
대한의사협회지
2021 .09
-
Landscape of inflammatory bowel disease in Singapore
Intestinal research
2022 .07
-
Concomitant ankylosing spondylitis can increase the risk of biologics or small molecule therapies to control inflammatory bowel disease
Intestinal research
2023 .04
-
Disability due to Inflammatory Bowel Disease Is Correlated with Drug Compliance, Disease Activity, and Quality of Life
Gut and Liver
2017 .01
-
Mechanism-based Drug Therapy of Inflammatory Bowel Disease With Special Reference to Rheumatic Disease
대한류마티스학회지
2020 .01
-
Nutritional approach as therapeutic manipulation in inflammatory bowel disease
Intestinal research
2019 .01
-
Effect of acid-reducing agents on clinical relapse in ulcerative colitis with pH-dependent-released 5-aminosalicylic acid: a multicenter retrospective study in Japan
Intestinal research
2021 .01
-
5-Aminosalicylic acid intolerance is associated with a risk of adverse clinical outcomes and dysbiosis in patients with ulcerative colitis
Intestinal research
2020 .01
-
Anti-inflammatory diet and inflammatory bowel disease: what clinicians and patients should know?
Intestinal research
2021 .01
-
Incidence and Prevalence of Inflammatory Bowel Disease across Asia
Yonsei Medical Journal
2021 .01
-
Maternal and fetal outcomes in pregnant Japanese women with inflammatory bowel disease: our experience with a series of 23 cases
Intestinal research
2017 .01
-
Erratum: Treatment of inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 2nd Asian Organization for Crohn’s and Colitis (AOCC) meeting in Seoul
Intestinal research
2016 .01
-
Natural history of inflammatory bowel disease: a comparison between the East and the West
Intestinal research
2022 .10
-
Aspirin Use Is Associated With Improved Outcomes in Inflammatory Breast Cancer Patients
Journal of Breast Cancer
2023 .02
-
Factors Associated with Anxiety and Depression in Korean Patients with Inactive Inflammatory Bowel Disease
Gut and Liver
2016 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0